Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells|
- Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs' on their maturation and the capacity to present [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2007|
|Study Completion Date:||March 2011|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00630721
|United States, North Carolina|
|University of North Carolina|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Silva Markovic-Plese, MD||UNC Chapel Hill|